163
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia

ORCID Icon, , , , , , , , , & show all
Pages 3330-3332 | Received 10 Apr 2019, Accepted 18 May 2019, Published online: 04 Jun 2019

References

  • Etienne G, Guilhot J, Rea D. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305.
  • Saussele S, Richter J, Gruber FX, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised trial. Lancet Oncol. 2018;19:747–757.
  • Pfirrmann M, Mahon FX, Guilhot J, et al. Chronic myeloid leukemia patients were not different in molecular relapse after stopping imatinib in MR4 whether residual disease was detected or not – when adjusting for number of control transcripts. Haematologica. 2017;102:153.
  • Saußele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–1647.
  • Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17–23.
  • Fava C, Rege-Cambrin G, Dogliotti I, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104. DOI:10.3324/haematol.2018.205054
  • Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–430.
  • Benjamini O, Kantarjian H, Rios MB, et al. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014;55:2879–2886.
  • Russo D, Malagola M, Skert C, et al. Managing chronic myeloid leukemia in the elderly with intermittent imatinib treatment. Blood Cancer J. 2015;5:347.
  • Clark R, Polydoros F, Apperley J, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4:310–316.
  • Rea D, Cayuela TP, Dulucq S, et al. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED). Blood. 2017;130:318.
  • O’Hare T, Deininger MW. Toward a cure for chronic myeloid leukemia. Clin Cancer Res. 2008;14:7971–7974.
  • NCCN Guidelines Version 1.2019 Chronic Myeloid Leukemia Version 1. 2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.